Facebook Facebook Share

Target Ovarian Cancer responds to consultations from the government, the NHS, and bodies responsible for clinical guidelines when they plan to change an existing, or introduce a new, policy or set of guidelines. Our responses reflect the priorities of women with ovarian cancer and the changes needed to improve diagnosis and treatment.

Long term plan for the NHS in England September 2018 

The government has recently announced an increase in NHS funding in England over five years, beginning in 2019/20. As part of this funding settlement NHS England have been asked to produce a 10-year plan for how this money will be used. Target Ovarian Cancer had the opportunity to submit evidence to NHS England to help shape a long term plan for cancer and inform them of our priorities. We used a survey to collect thoughts and opinions from women with an ovarian cancer diagnosis to additionally inform our response, which you can read below.

Target Ovarian Cancer - NHS long term plan submission

National Institute for Health and Care Excellence appraisal of niraparib

The National Institute for Health and Care Excellence (NICE) is currently considering whether new cancer drug niraparib (Zejula®) can be funded on the NHS. Target Ovarian Cancer responded to the initial consultation which was focused on the need for new treatments for ovarian cancer. We then gave evidence at the NICE Committee meeting considering niraparib and responded to a further more detailed consultation on funding for niraparib. NICE has said it will publish its final decision in June.

Read our response to NICE’s initial consultation for niraparib – September 2017

Niraparib - Patient carer organisation submission - Target Ovarian Cancer

Read the Appraisal Consultation Document (ACD) – February 2018

Niraparib - Appraisal Consultation Document

Read our response to the ACD – February 2018

Niraparib - ACD stakeholder comments - Target Ovarian Cancer

Proposed changes to how the National Institute for Health and Care Excellence (NICE) evaluates and funds new drugs - October 2016 – January 2017

NHS England and NICE consulted on changes to how new drugs are evaluated and funded, including a proposal for a further process for any new drug expected to cost the NHS £20 million a year or more.

Read the consultation document

Proposals for changes to how NICE evaluates and funds new drugs

Read our response

Proposals for changes to NICE evaluations - a response from Target Ovarian Cancer - January 2017

Proposed changes to Clinical Reference Groups (CRGs) - February 2016 – March 2016

CRGs are responsible for setting the standards to which services for more specialised care, including for ovarian cancer, are commissioned. This consultation looked at how they are structured.

Read the consultation document

Proposed revisions to Clinical Reference Groups

Read our response

Proposed revisions to Clinical Reference Groups - a response from Target Ovarian Cancer - March 2016

Changes to the Cancer Drugs Fund - November 2015 – February 2016

NHS England and National Institute for Health and Care Excellence consultation on changes to the Cancer Drugs Fund.

Read the consultation document

Consultation on proposals for a new Cancer Drugs Fund

Read our response

Consultation on proposals for a new Cancer Drugs Fund - a response from Target Ovarian Cancer - February 2016

Genetic testing for BRCA1 and BRCA2 mutations - March 2015 – April 2015

Following new guidelines in 2013 which recommended that all women with non-mucinous ovarian cancer be offered genetic, NHS England consulted on how this should be commissioned.

Read the consultation document

Clinical Commissioning Policy on genetic testing for BRCA1 and BRCA2 mutations

Read our response

Draft Clinical Commissioning Policy - genetic testing for BRCA1 and BRCA2 mutations - a response from Target Ovarian Cancer - April 2015

Call for evidence for new cancer strategy for England - November 2014 – February 2015

The Government asked Sir Harpal Kumar, Chief Executive of Cancer Research UK, to lead an independent taskforce to develop a new five year cancer strategy for England.

Read our response

Cancer strategy taskforce - a response from Target Ovarian Cancer - February 2015